Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.Pfizer (PFE 1.03%) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.It has developed many medicines over the years; most recently, it has been known for developing its highly successful COVID vaccine Comirnaty. Growth and innovation have enabled the company to become a household name and a leader ...

Two Indian drugmakers have come under regulatory scrutiny after cough syrups made by them were linked to a number of child deaths in Madhya Pradesh and Rajasthan. The central drug regulator has swung into action after finding a toxic contaminant in one of the cough syrups tested. Some states have banned the sale of these drugs. This isn’t the first time cough syrups made in India have been linked to fatalities in children. In recent years, India-made cough syrups have come under global scrutiny—they have be ...

We revisit Sanofi (NASDAQ: SNY ) ( OTCPK:SNYNF ) ( GCVRZ ) after our downgrade in early May 2024, a move that has so far been validated by the market, with the S&P 500 delivering double-digitBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must be treated as such. We take no ...

公司投资动态 - 赛诺菲宣布向赛诺菲风险投资基金追加6.25亿美元投资 使该基金总资产超过14亿美元 [1] - 此次投资旨在支持该基金长期专注于生物技术和数字健康领域的初创公司 [2] - 赛诺菲风险投资基金自2012年成立以来 已向全球约70家公司投资超过8亿美元 投资阶段覆盖从早期种子轮到IPO [2] - 该基金通过参与被投公司董事会和协助退出等方式提供支持 [2] 公司业务概况 - 赛诺菲是一家总部位于法国的全球医疗保健公司 [3] - 公司业务包括药品、疫苗和消费者保健产品的研发、开发、生产和营销 [3]

公司评级与市场观点 - 伯恩斯坦分析师Courtney Breen重申对默克公司的持有评级但未披露目标价 [1] - 默克公司被列为当前值得购买的最佳且便宜的股票之一 [1] 财务业绩与展望 - 公司2025年第二季度每股收益为213美元超出华尔街预期010美元 [2] - 2025年第二季度收入为1581亿美元同比下降190%低于预期6669万美元 [2] - 管理层将2025年全年收入指引更新为643亿美元至653亿美元此前指引为641亿美元至656亿美元 [3] 公司业务概况 - 默克公司是一家全球医疗保健公司业务涵盖开发销售处方药疫苗和动物健康产品 [3]

Pfizer Inc. (NYSE:PFE) is one of the Best and Cheap Stocks to Buy Right Now. On September 30, Reuters reported that Pfizer Inc. (NYSE:PFE) and President Donald Trump had announced a deal to lower Medicaid drug prices in the US. The company agreed to match its Medicaid prices to those it charges in other developed countries in exchange for tariff relief on its imports. President Trump noted that Pfizer Inc. (NYSE:PFE) will offer its most favoured nation prices on all new drugs launched in the United States ...

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer put under the microscope. Cramer recalled his discussion with the company’s CEO, and commented: “What else might work? Last Friday on the show, we had Joaquin Duato. He’s the CEO of Johnson & Johnson, and he told a remarkable story about game-changing cancer drugs and medical devices, especially their excellent cardio products. Now, I’ve been worried about the talc lawsuits that they have, but I believe the risk from the asbestos and the baby po ...

公司核心产品与前景 - 公司GLP-1药物被强调用于糖尿病和减肥 并被认为未来可能应用于高血压、痴呆及酒精中毒等更广泛领域[1] - 公司股票表现因该药物的给药方式欠佳而受到阻碍[1] 公司战略与投资 - 公司计划投资65亿美元以加强其产品管线的生产能力[2] - 公司业务涵盖糖尿病、肥胖症、肿瘤学、免疫学、神经科学及胃肠道疾病等领域药物的开发与销售[2]

股市整体表现 - 尽管联邦政府停摆进入第三天 但股市表现强劲 标普500指数周五小幅上涨 创下自4月初关税低点以来的第29个收盘纪录新高[1] - 纳斯达克指数周五小幅下跌 但其在周四创下了自4月初以来的第30个收盘纪录[1] - 两大指数在过去五周中有四周上涨 在强劲的9月和第三季度表现后 为新月份开了个好头[1] - 市场认为政府停摆影响不大 分析师Jim Cramer在停摆前表示此为“非事件” 并建议投资者无需担忧[1] 行业与板块表现 - 医疗健康板块成为本周标普500指数11个板块中表现最强者 主要受特朗普总统与辉瑞协议提振 该协议豁免辉瑞药品关税以换取其降价售药和增加在美国制造业投资的承诺[1] - 公用事业和信息技术板块分别位列本周表现第二和第三 人工智能交易持续活跃 公用事业因运行AI数据中心所需电力而获得提振[1] - 信息技术板块上涨 因俱乐部持股公司英伟达股价在周四飙升至纪录新高[1] 重点公司动态 - 生命科学公司丹纳赫股价飙升超过16% 制药公司礼来股价跳涨近16% 成为投资组合中本周最佳股票[1] - 公用事业公司AES股价大涨 因有报道称贝莱德旗下全球基础设施合作伙伴正以380亿美元的价格洽谈收购该公司[1] - 贝莱德收购的基础设施基金管理公司GIP据称也正在洽谈以约400亿美元收购Aligned Data Centers[1] - 耐克公司在周二晚间公布季度收益远超华尔街预期后股价上涨 营收原本预计下降中个位数百分比 但实际增长了1% 显示其扭亏为盈战略取得进展[1] - 波音公司股票在周二被买入 因其股价出人意料地回吐了上周美国联邦航空管理局放松限制消息带来的大部分涨幅 FAA的公告被视为利好 因其允许波音更轻松地增加产量[1] - 波音新型777X宽体喷气式飞机预计将在2027年初进行商业首飞 而非原计划的明年 该项目进度落后于计划[1] - 好市多公司股票在周二被少量增持 该公司市场份额持续增长且具有持久增长故事 尽管上季度业绩未达预期 但会员增长和毛利率扩张令人欣慰[1] - 俱乐部在周三减持了百时美施贵宝股票以筹集现金 尽管该股本周在特朗普-辉瑞协议引发的大型制药股反弹中上涨 但此次减持导致对2024年11月购入的该股票产生了约20%的亏损[1] 华尔街机构观点与评级变动 - 摩根士丹利将富国银行评级从增持下调至持有 理由是该行在美联储取消1.95万亿美元资产上限后缺乏近期催化剂 且不会成为美联储降息的受益者 净利息收入增长空间有限[1] - 加拿大皇家银行资本市场将GE Vernova股票评级从买入下调至持有 并将其目标股价从631美元下调至605美元 理由是其风力涡轮机业务面临挑战以及对其估值的担忧[1] - 杰富瑞将苹果公司评级从持有下调至逊于大盘 认为最新iPhone 17和Air机型的需求已被股价消化 且对明年可折叠iPhone 18的预期过高[1] - 但分析认为应忽略杰富瑞的报告 因杰富瑞今年内已五次调整苹果评级 且苹果公司在iPhone创新方面仍有潜力 虽不常率先推出新品 但历来提供最佳质量[2]

In this article, I will explain—using back-of-the-envelope math and plain English—why the stock of Viking Therapeutics, Inc. (NASDAQ: VKTX ), one of the frontrunners in the GLP-1 weight-loss drug market, may represent a (relatively) de-risked investment opportunityI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been ope ...